What glutathione actually does inside your cells
Glutathione (GSH) is a tripeptide assembled from three amino acids: glutamate, cysteine, and glycine. It is the most abundant antioxidant found inside human cells, present in millimolar concentrations in tissues like the liver, kidneys, lungs, and brain. Unlike vitamins C or E, which circulate in the blood, glutathione works primarily inside cells, where oxidative damage actually begins.
Its functions are extensive. Glutathione neutralizes reactive oxygen species (ROS) before they damage cell membranes, proteins, and DNA. It acts as a critical cofactor for a family of detoxifying enzymes called glutathione S-transferases, which the liver uses to process and excrete environmental toxins, heavy metals, and drug metabolites. It regenerates other antioxidants, including vitamins C and E, back to their active forms after they have neutralized free radicals. It also plays a direct role in immune cell proliferation and the inflammatory response.
When glutathione is insufficient, oxidative stress accumulates unchecked. This is not a peripheral issue. Researchers studying aging, metabolic disease, cardiovascular disease, neurodegeneration, and chronic inflammation consistently find depleted glutathione as a unifying feature.
What the decline looks like: Clinical studies comparing older adults (61 to 80 years) to young adults (21 to 40 years) have found the ratio of reduced-to-oxidized glutathione drops from roughly 10:1 in young adults to just over 1:1 in older adults. That ratio is a proxy for how much antioxidant capacity is actually available. A 10:1 ratio means your cells are handling oxidative load. A 1:1 ratio means you have almost no reserve.
The problem with taking NAC by itself
N-acetylcysteine (NAC) has been the go-to glutathione precursor for years, and for good reason: cysteine is the rate-limiting building block for glutathione synthesis, and NAC is a stable, bioavailable form that converts to cysteine after absorption. Emergency medicine uses high-dose NAC intravenously to treat acetaminophen overdose precisely because it rapidly replenishes hepatic glutathione.
But here is where the picture gets complicated. Glutathione is not a single-ingredient synthesis. It requires three amino acids, and the synthesis happens in two enzymatic steps. The first step combines glutamate and cysteine. The second adds glycine to complete the tripeptide. If cysteine is one bottleneck, glycine is the other. As we age, both the supply of these precursors and the activity of the synthesizing enzymes decline simultaneously.
Clinical trials supplementing NAC alone in older adults have repeatedly failed to raise red blood cell glutathione concentrations, reduce circulating markers of oxidative stress, or lower inflammatory cytokines like TNF-alpha. The cysteine supply increases, but the glycine deficit remains untouched, and the synthesis enzymes still cannot run at full capacity.
The key finding: In head-to-head comparisons in aged mice, NAC alone did not improve cardiac function or reduce inflammatory cell infiltration. The combination of glycine and NAC did. Human trials supplementing NAC alone showed no meaningful improvements in blood glutathione, oxidative stress markers, or inflammation. The combination corrected all three.
Why you cannot just take a glutathione supplement
This is one of the more consequential misunderstandings in the supplement space. Walk into any health food store and you will find glutathione capsules marketed as a direct way to raise your levels. The biochemistry says otherwise.
Glutathione is a fragile tripeptide. The gastrointestinal tract contains an enzyme called gamma-glutamyltransferase that actively degrades it. Standard oral glutathione has bioavailability below 5%, and a landmark study in the European Journal of Clinical Pharmacology demonstrated that even a single 3,000 mg oral dose of glutathione did not produce a clinically meaningful increase in blood glutathione levels.
The body's strategy for maintaining intracellular glutathione is not to absorb it from food or supplements. Each cell synthesizes its own, on demand, according to its metabolic requirements. This is deliberate: too little glutathione fails to neutralize oxidative stress, but too much triggers a harmful state of reductive stress that accelerates cellular aging. The body regulates this balance through synthesis rather than absorption.
This is precisely why providing the two rate-limiting precursors, cysteine and glycine, is a fundamentally more intelligent strategy than attempting to deliver the finished molecule. You are handing the cell the raw materials and letting it produce exactly as much as it needs.
The GlyNAC research: what the clinical trials found
The most rigorous body of evidence comes from Dr. Rajagopal Sekhar's lab at Baylor College of Medicine, which has been running GlyNAC trials for over a decade across healthy aging adults, adults with HIV-associated premature aging, and patients with diabetes.
In the landmark 2023 randomized controlled trial published in the Journals of Gerontology, 24 older adults were randomized to receive either GlyNAC or an isonitrogenous placebo for 16 weeks, alongside 12 young adults who received GlyNAC for 2 weeks as a reference group. The results across the older adult GlyNAC group were striking. After 16 weeks, participants showed correction of glutathione deficiency in both muscle tissue and red blood cells. Oxidative stress markers dropped substantially. Mitochondrial function improved, with a significant shift from the dysfunctional pattern of glucose-dependent energy production toward the healthier pattern of fatty-acid oxidation. Markers of systemic inflammation declined. Insulin resistance improved. Measures of physical function, including gait speed and 6-minute walking distance, increased meaningfully.
Critically, none of these improvements were seen in the placebo group. And none of them were sustained after participants stopped supplementing for 12 weeks, which tells you that ongoing depletion of these precursors is the ongoing driver of the deficit.
The "Power of 3": Sekhar's team attributes the results not to glutathione alone, but to what they call the "Power of 3": the independent contributions of glycine, NAC (as a cysteine donor), and the intracellular glutathione that they together produce. Glycine and cysteine each have their own cellular roles beyond glutathione synthesis, which may explain why the combination produces broader effects than simply raising GSH alone.
Who is most likely to be depleted
Glutathione deficiency is not equally distributed. Certain populations face significantly higher depletion rates and stand to benefit most from this pairing.
Adults over 40. The decline in glutathione synthesis is gradual and begins in middle age. By the time most people notice increased fatigue, slower recovery, or general metabolic sluggishness, their intracellular GSH has already been low for years. The deficiency tends to be asymptomatic until it becomes severe.
People with type 2 diabetes or metabolic syndrome. Multiple Sekhar lab studies recruited subjects with insulin resistance specifically because their glutathione depletion is particularly severe, likely because chronic hyperglycemia generates a high and continuous load of oxidative stress that accelerates GSH consumption. GlyNAC trials in this population showed among the most dramatic improvements.
Heavy exercisers and athletes. Intense training generates significant oxidative stress as a byproduct. The body responds by upregulating antioxidant defenses over time, but this adaptation requires adequate precursor availability. Athletes who train hard but do not recover well, and who are not deliberately supporting antioxidant capacity, are likely running on a depleted system.
Anyone with significant alcohol intake or liver disease. The liver is the central hub for glutathione synthesis and storage. Alcohol directly depletes hepatic glutathione and impairs the activity of the synthesis enzymes. Liver disease compounds this further. NAC is used clinically in liver disease for exactly this reason, but the glycine component has been consistently overlooked in clinical practice.
What to actually take, and in what ratio
The GlyNAC protocol used in Sekhar's trials dosed glycine and NAC at a 1:1 ratio by weight, at 100 mg per kilogram of body weight per day for each compound. For a 70 kg adult, that translates to roughly 7 grams each of glycine and NAC daily, split across two doses. This is the research-grade dose used to produce the full reversal of aging markers seen in the trials.
For practical supplementation in otherwise healthy adults under 60, a more conservative and well-tolerated starting point is 1.8 to 3 grams each of glycine and NAC per day, in a roughly 1:1 ratio, taken with a meal. NAC on an empty stomach causes nausea in a significant proportion of users. The combination is generally better tolerated with food.
Glycine powder is widely available and extremely inexpensive, often costing less than two cents per gram in bulk form. This is relevant because many people already take NAC and simply need to add glycine to complete the pair. The cost of restoring the missing half of this equation is almost trivial.
NAC at 600mg twice daily provides 1.2g of cysteine precursor. Match with 1g glycine powder or capsules twice daily to maintain the studied ratio. Glycine powder dissolves in water and has a mildly sweet taste, making it easy to add to any morning drink.
View NAC on Amazon →Bulk glycine powder from a reputable supplier is the most cost-effective approach. At 1 kg for around $20, a full research-level dose costs under $1.50 per day. This is one of the highest-value longevity interventions available by cost-per-effect.
View Glycine Powder on Amazon →Timing, interactions, and important cautions
NAC has a meaningful interaction with nitroglycerin and other nitrate medications used for angina. If you are on any nitrate-based cardiac medication, speak to your physician before starting NAC. High-dose NAC has also been shown in some cell and animal studies to potentially interfere with the pro-oxidant environment that some cancer treatments intentionally create inside tumor cells; this is theoretical at supplemental doses in humans, but it is a reasonable reason for anyone currently undergoing chemotherapy to discuss NAC with their oncologist first.
Beyond these populations, GlyNAC is considered safe and well-tolerated. The 16-week Sekhar trial and the Frontiers in Aging 2022 study in 114 healthy older adults both reported no significant adverse events. Glycine is an amino acid naturally present in collagen-rich foods and has an excellent safety profile at the doses used here.
A note on timing with food: Take both compounds with meals to minimize the nausea that NAC can cause on an empty stomach. There is no compelling evidence that taking this combination in the morning versus the evening makes a meaningful difference. Consistency matters more than timing.
What to expect, and over what timeframe
The Sekhar trials used 16 weeks as their treatment period for measuring full effects, and benefits declined significantly after 12 weeks off supplementation. This suggests that improvements in glutathione status, oxidative stress, and mitochondrial function require sustained precursor supply and are not a one-time correction. Think of it less like a treatment and more like ongoing nutritional support for a system that aging has made chronically undersupplied.
Subjective improvements in energy and recovery are commonly reported anecdotally within 4 to 8 weeks. The objective markers studied in clinical trials, including gait speed, walking capacity, and metabolic markers, required the full 16 weeks to reach statistical significance. If you are tracking this protocol, give it at least three months before evaluating.